Machine Learning Analysis of SIRI Impact on Cardiovascular Risk in Gout Patients

Overview

This retrospective study analyzed data from 1,260 gout patients in NHANES 2007–2018 using machine learning to evaluate the association between the Systemic Inflammation Response Index (SIRI) and cardiovascular disease (CVD) risk. Findings suggest that elevated SIRI, reflecting systemic inflammation, correlates with increased CVD incidence in gout patients, highlighting its potential as a comprehensive risk assessment tool.

Background

Gout is a prevalent inflammatory joint disease characterized by hyperuricemia and chronic inflammation, affecting millions globally. It is associated with increased cardiovascular morbidity and mortality, with gout patients exhibiting higher rates of hypertension, heart failure, and coronary heart disease. Traditional CVD risk assessments in gout focus mainly on uric acid levels, lacking comprehensive inflammatory markers. The Systemic Inflammation Response Index (SIRI), derived from neutrophil, monocyte, and lymphocyte counts, has emerged as a promising marker reflecting systemic inflammation and organ dysfunction, but its role in gout-related CVD risk remains underexplored.

Data Highlights

From an initial NHANES cohort of 59,842 participants, 1,260 gout patients aged ≥20 years with complete data on SIRI and CVD status were analyzed. Cardiovascular outcomes assessed included congestive heart failure, coronary heart disease, angina, myocardial infarction, and stroke. SIRI was calculated integrating neutrophil, monocyte, and lymphocyte counts. Machine learning models incorporated demographic, clinical, and laboratory variables to evaluate the predictive value of SIRI for CVD risk in gout patients.

Key Findings

• Gout patients exhibited a significantly higher incidence of cardiovascular diseases compared to the general population.
• Elevated SIRI levels were associated with increased risk of multiple CVD outcomes, including heart failure, coronary heart disease, and stroke.
• Machine learning models demonstrated that incorporating SIRI improved the accuracy of CVD risk prediction beyond traditional factors such as age, cholesterol, and blood pressure.
• SIRI effectively reflected systemic inflammation and organ function impairment in gout patients, linking inflammatory burden to cardiovascular risk.
• The study validated the use of SIRI as a novel, accessible biomarker for comprehensive cardiovascular risk assessment in gout populations.

Clinical Implications

Clinicians should consider incorporating SIRI into cardiovascular risk assessments for gout patients to better identify individuals at high risk for adverse cardiovascular events. This index, derived from routine blood counts, offers a cost-effective and practical tool to capture systemic inflammation beyond serum uric acid levels. Early identification of elevated SIRI may prompt more aggressive management of cardiovascular risk factors in gout patients.

Conclusion

The study supports the utility of SIRI as a valuable biomarker linking systemic inflammation to cardiovascular disease risk in gout patients. Integrating SIRI into clinical practice may enhance risk stratification and guide targeted interventions to reduce cardiovascular morbidity and mortality in this high-risk population.

References

1. Kuo et al. 2015 -- Epidemiology and Clinical Features of Gout
2. Chen et al. 2019 -- Global Burden of Gout and Hyperuricemia
3. Zhou et al. 2020 -- Gout Prevalence in China
4. Smith et al. 2018 -- Cardiovascular Disease and Gout
5. Wang et al. 2021 -- SIRI and Cardiovascular Risk
6. CDC NHANES 2007-2018 -- National Health and Nutrition Examination Survey
7. Framingham Heart Study -- CVD Risk Functions